KR102511874B1 - 개선된 백신 및 이의 사용 방법 - Google Patents

개선된 백신 및 이의 사용 방법 Download PDF

Info

Publication number
KR102511874B1
KR102511874B1 KR1020217039157A KR20217039157A KR102511874B1 KR 102511874 B1 KR102511874 B1 KR 102511874B1 KR 1020217039157 A KR1020217039157 A KR 1020217039157A KR 20217039157 A KR20217039157 A KR 20217039157A KR 102511874 B1 KR102511874 B1 KR 102511874B1
Authority
KR
South Korea
Prior art keywords
seq
nucleotides
amino acids
less
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217039157A
Other languages
English (en)
Korean (ko)
Other versions
KR20210151987A (ko
Inventor
데이비드 비. 웨이너
지안 얀
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority to KR1020237009029A priority Critical patent/KR20230042399A/ko
Publication of KR20210151987A publication Critical patent/KR20210151987A/ko
Application granted granted Critical
Publication of KR102511874B1 publication Critical patent/KR102511874B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217039157A 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법 Active KR102511874B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237009029A KR20230042399A (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US83386106P 2006-07-28 2006-07-28
US83385606P 2006-07-28 2006-07-28
US60/833,861 2006-07-28
US60/833,856 2006-07-28
US89035207P 2007-02-16 2007-02-16
US60/890,352 2007-02-16
PCT/US2007/074769 WO2008014521A2 (en) 2006-07-28 2007-07-30 Improved vaccines and methods for using the same
KR1020207031173A KR102334637B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031173A Division KR102334637B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237009029A Division KR20230042399A (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20210151987A KR20210151987A (ko) 2021-12-14
KR102511874B1 true KR102511874B1 (ko) 2023-03-20

Family

ID=38982433

Family Applications (10)

Application Number Title Priority Date Filing Date
KR1020217039157A Active KR102511874B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020247035070A Ceased KR20240159010A (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020177004941A Active KR101848867B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020097004232A Active KR101562888B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020187010028A Active KR101999376B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020237009029A Ceased KR20230042399A (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020147035344A Active KR101609235B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020167007633A Active KR101710981B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020197019662A Active KR102173636B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020207031173A Active KR102334637B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법

Family Applications After (9)

Application Number Title Priority Date Filing Date
KR1020247035070A Ceased KR20240159010A (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020177004941A Active KR101848867B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020097004232A Active KR101562888B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020187010028A Active KR101999376B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020237009029A Ceased KR20230042399A (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020147035344A Active KR101609235B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020167007633A Active KR101710981B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020197019662A Active KR102173636B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020207031173A Active KR102334637B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법

Country Status (12)

Country Link
US (4) US8168769B2 (https=)
EP (7) EP2594576B1 (https=)
JP (9) JP2009544333A (https=)
KR (10) KR102511874B1 (https=)
CN (3) CN105132439A (https=)
AU (4) AU2007278831B2 (https=)
CA (4) CA2949851C (https=)
DK (2) DK3037429T3 (https=)
ES (2) ES2589013T3 (https=)
HK (1) HK1218427A1 (https=)
MX (3) MX346862B (https=)
WO (1) WO2008014521A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007278831B2 (en) * 2006-07-28 2013-03-21 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US8926961B2 (en) * 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
EP2217064A4 (en) * 2007-11-12 2012-10-03 Univ Pennsylvania NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US8795430B2 (en) 2009-03-02 2014-08-05 The Regents Of The University Of California Method of improving surface morphology of (Ga,Al,In,B)N thin films and devices grown on nonpolar or semipolar (Ga,Al,In,B)N substrates
CN102821790A (zh) * 2009-09-14 2012-12-12 宾夕法尼亚大学托管会 包含IL-15受体α和/或编码IL-15受体α的核酸分子的疫苗和免疫治疗剂,以及其使用方法
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CA2788902C (en) * 2010-02-08 2019-09-03 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
EP2536830B1 (en) 2010-02-16 2019-07-17 Ultimovacs AS Polypeptides
US8932575B2 (en) 2010-09-21 2015-01-13 University Of Miami Compositions and methods for inducing migration by dendritic cells and an immune response
WO2012040266A2 (en) * 2010-09-24 2012-03-29 University Of Miami Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
JP2013544504A (ja) * 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
CN114277038A (zh) * 2011-10-12 2022-04-05 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的疫苗及其使用方法
KR20140116095A (ko) 2011-12-12 2014-10-01 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Mrsa pbp2a 및 이의 단편들을 포함하는 단백질, 이를 인코딩한 핵산, 및 mrsa 감염을 예방 및 치료하기 위한 조성물 및 그의 용도
SG11201501646PA (en) * 2012-09-07 2015-04-29 Agency Science Tech & Res Peptides and their uses
CN103172705B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
CN103102394B (zh) * 2013-02-27 2014-06-25 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi49及其应用
CN103113458B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
WO2014165291A1 (en) * 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
AU2014228405B2 (en) 2013-03-15 2017-05-11 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
KR20220061285A (ko) * 2013-11-14 2022-05-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 HIV-1 EnV DNA 백신과 단백질 부스터
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
CA2974956A1 (en) * 2015-01-29 2016-08-04 The Trustees Of The University Of Pennsylvania Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
MX2018009506A (es) * 2016-02-05 2019-05-06 Inovio Pharmaceuticals Inc Vacunas contra el cáncer y métodos de tratamiento que las utilizan.
CN109069575A (zh) * 2016-02-23 2018-12-21 毛里齐奥·扎内蒂 通用癌症疫苗
KR20230167445A (ko) * 2016-09-30 2023-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Tert 면역원성 조성물 및 이를 이용한 치료 방법
WO2018156106A1 (en) * 2017-02-22 2018-08-30 Ding Enyu An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes
CN109142723B (zh) * 2018-08-21 2021-07-13 苏州华益美生物科技有限公司 人类免疫缺陷病毒快速检测测试卡及其应用
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
WO2021202949A2 (en) * 2020-04-02 2021-10-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US2579A (en) 1842-04-21 Flour-ing-mill combining a smut-machine with the scouring-stones
US2157994A (en) 1937-11-08 1939-05-09 Kelsey Hayes Wheel Co Brake mechanism
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
JP3044062B2 (ja) 1989-03-08 2000-05-22 ヘルス・リサーチ・インク 組換えポックスウイルス宿主選択系
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
EP0465560B1 (en) 1989-03-31 1996-06-05 Washington University VACCINES CONTAINING AVIRULENT phoP-TYPE MICROORGANISMS
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US6183745B1 (en) * 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
KR100252371B1 (ko) * 1990-12-12 2000-05-01 포터 더글라스 서브유니트 파필로마비루스 백신 및 그들에 사용하기 위한 펩티드
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
AU675702B2 (en) 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
EP0708659A4 (en) 1993-06-07 2000-08-23 Genentech Inc HIV ENVELOPE POLYPEPTIDES
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
US5703655A (en) 1995-03-24 1997-12-30 U S West Technologies, Inc. Video programming retrieval using extracted closed caption data which has been partitioned and stored to facilitate a search and retrieval process
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US7585622B1 (en) * 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
EP0932686A2 (en) * 1996-10-01 1999-08-04 Geron Corporation Telomerase reverse transcriptase
CN1240480A (zh) * 1996-10-18 2000-01-05 坎吉有限公司 运送和表达干扰素－α核酸的方法和组合物
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
DE19720914A1 (de) * 1997-05-16 1998-11-19 Boehringer Mannheim Gmbh Verfahren zum Nachweis von HIV-Antikörpern und dazu verwendete Antigene
KR100581990B1 (ko) * 1997-07-01 2006-05-23 캄비아 바이오시스템즈 엘엘씨 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU752725B2 (en) 1997-09-18 2002-09-26 Trustees Of The University Of Pennsylvania, The Attenuated vif DNA immunization cassettes for genetic vaccines
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
FR2794368A1 (fr) * 1999-10-07 2000-12-08 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7488484B2 (en) 2000-07-14 2009-02-10 The Trustees Of The University Of Pennsylvania Nucleic acid expression cassette encoding an HIV polyprotein comprising the ancillary gene products Vif, Vpu, and Nef
AU1152402A (en) * 2000-10-04 2002-04-15 Univ Pennsylvania Highly expressible genes
EP1195438A1 (en) * 2000-10-06 2002-04-10 Rijksuniversiteit te Groningen Genetic immunisation against cervical carcinoma
US20040171081A1 (en) * 2001-11-23 2004-09-02 Abraham Mittelman Antigens
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
CN1468956A (zh) * 2002-07-15 2004-01-21 杨 琴 高效表达治疗肿瘤的抗体的重组病毒及其用途
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
DE60332377D1 (de) * 2002-10-21 2010-06-10 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
CN1453361A (zh) * 2003-05-30 2003-11-05 中国科学院上海生命科学研究院 一种抗癌靶向可调控基因－病毒的构建方法
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
CA2539325C (en) * 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens
WO2005028634A2 (en) * 2003-09-18 2005-03-31 Emory University Improved mva vaccines
JP2007528838A (ja) * 2003-12-24 2007-10-18 ライデン ユニバーシティ メディカル センター 腫瘍特異的ワクチンとしての合成タンパク質
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
EP1732615A4 (en) * 2004-03-25 2009-09-16 Kentucky Bioproc Llc PREPARATION OF PEPTIDES IN PLANTS AS VIRUS SHELL PROTEIN FUSION
CN1775802A (zh) * 2004-11-17 2006-05-24 宋硕 人类乳头瘤病毒免疫原性多肽、其制备方法及应用
ATE541938T1 (de) * 2005-04-29 2012-02-15 Univ Cape Town Expression viraler proteine in pflanzen
EP1909829A4 (en) * 2005-07-19 2009-11-11 Dow Global Technologies Inc RECOMBINANT GRIP VACCINES
AU2007278831B2 (en) * 2006-07-28 2013-03-21 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
EP2076531B1 (en) * 2006-10-12 2011-11-23 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
GB2504774A (en) 2012-08-10 2014-02-12 Munster Simms Eng Ltd Diaphragm pump with integral motor housing and rear pump housing
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gao, F. et al., J Virol (2005) 79:1154-1163

Also Published As

Publication number Publication date
EP4400510A2 (en) 2024-07-17
JP6186333B2 (ja) 2017-08-23
JP2018108110A (ja) 2018-07-12
KR20240159010A (ko) 2024-11-05
KR20210151987A (ko) 2021-12-14
CA2659262A1 (en) 2008-01-31
EP3907232A1 (en) 2021-11-10
KR20180041247A (ko) 2018-04-23
CA3057039C (en) 2023-02-28
JP2020103317A (ja) 2020-07-09
HK1130807A1 (en) 2010-01-08
KR20090046899A (ko) 2009-05-11
US8168769B2 (en) 2012-05-01
US20140341941A1 (en) 2014-11-20
WO2008014521A3 (en) 2008-12-24
AU2024200014B2 (en) 2025-11-27
JP2016029105A (ja) 2016-03-03
CN101679475A (zh) 2010-03-24
EP3907232B1 (en) 2024-02-21
CA3057039A1 (en) 2008-01-31
KR20190083680A (ko) 2019-07-12
EP2594576B1 (en) 2015-07-01
JP6097086B2 (ja) 2017-03-15
KR102173636B1 (ko) 2020-11-04
JP2022081665A (ja) 2022-05-31
AU2026201472A1 (en) 2026-03-19
JP2013081482A (ja) 2013-05-09
JP2025032154A (ja) 2025-03-11
EP2708549A3 (en) 2014-05-21
HK1218427A1 (zh) 2017-02-17
US9376471B2 (en) 2016-06-28
DK2049559T3 (da) 2013-03-25
EP2049559A4 (en) 2011-03-02
CN105063064B (zh) 2024-09-24
KR101562888B1 (ko) 2015-10-26
WO2008014521A8 (en) 2012-06-14
CA3184778A1 (en) 2008-01-31
MX346862B (es) 2017-04-04
WO2008014521A2 (en) 2008-01-31
AU2007278831B2 (en) 2013-03-21
KR20200126024A (ko) 2020-11-05
CA2949851A1 (en) 2008-01-31
EP3037429A1 (en) 2016-06-29
CN105063064A (zh) 2015-11-18
MX2009001099A (es) 2009-02-10
JP7030347B2 (ja) 2022-03-07
KR101609235B1 (ko) 2016-04-05
DK3037429T3 (en) 2019-01-21
CN105132439A (zh) 2015-12-09
EP2049559B1 (en) 2012-12-19
JP6356653B2 (ja) 2018-07-11
EP2708549A2 (en) 2014-03-19
CA2949851C (en) 2019-11-12
AU2013201592B2 (en) 2015-03-12
EP2708549B1 (en) 2016-07-06
EP2594576A1 (en) 2013-05-22
KR20160038075A (ko) 2016-04-06
KR102334637B1 (ko) 2021-12-06
AU2024200014A1 (en) 2024-03-14
US20130004529A1 (en) 2013-01-03
EP3489251B1 (en) 2021-03-17
KR20150003921A (ko) 2015-01-09
KR101710981B1 (ko) 2017-02-28
US8697084B2 (en) 2014-04-15
KR101999376B1 (ko) 2019-07-11
CN101679475B (zh) 2015-08-12
EP3489251A1 (en) 2019-05-29
ES2706501T3 (es) 2019-03-29
MX340880B (es) 2016-07-28
KR20170024131A (ko) 2017-03-06
AU2007278831A1 (en) 2008-01-31
US9290546B2 (en) 2016-03-22
EP2049559A2 (en) 2009-04-22
ES2589013T3 (es) 2016-11-08
CA2659262C (en) 2017-01-10
KR101848867B1 (ko) 2018-04-13
JP2020103318A (ja) 2020-07-09
JP2009544333A (ja) 2009-12-17
EP4400510A3 (en) 2025-03-05
EP3037429B1 (en) 2018-09-26
US20100166787A1 (en) 2010-07-01
JP2015012874A (ja) 2015-01-22
US20140186384A1 (en) 2014-07-03
KR20230042399A (ko) 2023-03-28

Similar Documents

Publication Publication Date Title
KR102511874B1 (ko) 개선된 백신 및 이의 사용 방법
AU2021204612B2 (en) Improved vaccines and methods for using the same
HK40114241A (en) Improved vaccines and methods for using the same
HK40064045B (en) Improved hiv vaccines
HK40064045A (en) Improved hiv vaccines
HK1130807B (en) Improved hpv vaccines

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4